DOCSLIB.ORG

Valeant, the Serial Pharma Dealmaker Cuts Again

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Valeant, the Serial Pharma Dealmaker Cuts Again Valeant, the serial pharma dealmaker cuts again Valeant Pharmaceuticals International, Inc.; market cap (as of 26/02/2015): US$76.68bn Salix Pharmaceuticals, Ltd.; market cap (as of 26/02/2015): US$10.07bn Introduction The pharmaceutical industry has undergone an intense period of consolidation in the past 18 months which is far from over as the big players take advantage of the cheap credit to acquire the promising assets. On February 22, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for US$158 per share in cash. Valeant valued Salix at US$10bn plus US$4.5bn in debt amounting to a total enterprise value of approximately US$14.5bn. The deal represents Valeant’s biggest acquisition and brings the total amount Valeant has spent on acquisitions in the past five years to approximately US$30bn. Companies’ overview Salix Pharmaceuticals, headquartered in Raleigh, North Carolina, is a leader in the growing US gastrointestinal market with a portfolio of 22 total products, including its top- selling product Xifaxan, which treats diarrhea caused by irritable-bowel syndrome, as well as a strong near-term pipeline of innovative new assets. Valeant Pharmaceuticals International, based in Quebec, Canada, focuses on drugs treating skin, eye and neurological disorders. Traditionally, Valeant’s revenues stemmed from its various products rather than a blockbuster drug but this is bound to change after the acquisition takes place. Valeant will become extremely reliant on the sales of Xifaxan, Salix’s main drug. Namely, it expects one fourth of its sales to come from Salix’s gastrointestinal products. In 2010 Valeant relocated to Canada from the U.S. trough a tax inversion it undergone with Canada-based Biovail Corp. This way it managed to cut its effective tax rate to less than 5%. Also Salix tried cutting its tax bill last year, announcing a deal that would have moved its headquarters to Italy and cut its tax bill to the low 20%. However, the deal did not go through following the regulatory changes targeting corporate inversions. Valeant’s Acquisition Strategy Aiming to grow through inorganic way and benefitting from low interest rate environment, Valeant has always been an active player in deal-making business, especially after the appointment of the new CEO, J. Michael Pearson. Since 2008, the company has spent US$19bn on 40 acquisitions and its market value grew from US$1.7bn in 2008 to approximately US$77bn in 2015. The aggressive acquisition strategy of Valeant, which basically consists of increasing efficiency of targets, reducing extra spending and consolidating operations, has created tremendous gains for its shareholders. However, this strategy has raised concerns about the company’s debt burden as well as the attractiveness of its stock, which has been used as a form of payment in transactions. It has been accused of pursuing and unsustainable business model and destroying shareholders’ value by making big cuts to R&D spending. Indeed, after the unsuccessful acquisition attempt for Allergan, Valeant announced that it would focus on organic growth rather than acquisitions and pledged to spend up to US$2bn in order to buy back shares and pay down debt in an attempt to decrease the US$16.3bn outstanding debt, improve its Ba3 “junk status” rating and increase investor confidence in the company. However, the company’s dedication to organic growth and debt repayment has ended in a short time span as a result of the Salix deal, which brings about a massive increase in debt and boosts its ratio of net debt to EBITDA from below 4x to about 5.6x. The Deal in Details Valeant said it would finance the US$158/share cash offer with a US$22.2bn combination of bonds and bank loans. Banks led by Deutsche Bank and HSBC will provide about US$15bn of debt for the deal, and a further US$7.5bn to tide the group over while it secures a new agreement with existing creditors. As part of the financing package to fund Salix acquisition, it may have access to a US$5.5bn incremental loan facility and a US$9.6bn unsecured bridge loan. The bridge loan will be funded through the sale of corporate bonds in the high-yield market in the coming months. Moreover, a bond offer of that size would be the second-largest sale of junk debt, following a record offering by French cable operator Numericable in April 2014 that surpassed US$10bn. According to the release, the merger is expected to yield more than US$500m in annual cost savings within six months. This astonishing savings target represents 90x of US$560m that Salix expected to spend on research, marketing and overhead costs in 2014 on an adjusted basis. As a matter of fact, Valeant has done something similar to that before. Namely, it acquired Bausch & Lomb in 2013 and Medicis in 2012 with the same goal (although its saving targets were not as aggressive). The value extraction also comes from Valeant’s 5% tax rate compared to the 30% Salix was paying. Indeed, when the deal gets completed the combined company is expected to have a tax rate of 5%. After the announcement of the deal Valeant shares rose more than 13%. As previously mentioned value extraction will come from the cost savings and lower tax rate but another reason for this surge in the price is the expected increase in EPS: the transaction is expected to be modestly accretive to 2015 cash EPS, but over 20% accretive to 2016 cash EPS. On the other hand Salix’s shares closed at US$157.85 on Friday as news of the deal emerged. Its shares were trading around US$85 in recent months due to the recent accounting scandal. Accounting Scandal In 2014, Pharmaceutical industry has been a stage for a number of multi-billion dollar deals including tax inversions, last minute cancellations and regulatory issues such as Abbvie-Shire, Pfizer-AstraZeneca, Medtronic-Covidien and Actavis-Allergan. In fact, Valeant, which teamed up with Allergan’s largest shareholder, Pershing Square Capital and its manager Mr. Ackman, has relentlessly attempted to acquire Allergan and tried to escalate a proxy fight to gain more seats in Allergan’s board. To fend off Valeant’s hostile takeover attempts, Allergan decided to acquire Salix in order to make itself too big to swallow. However, after the due-diligence process, Allergan decided to pull out of the deal because wholesaler inventory levels for some key products of Salix were much higher than normal levels. This strategy, also called channel stuffing, is used by companies to inflate current period sales by selling products to wholesalers more than they can sell to their customers in the current period, resulting in depressed sales levels for future periods. Increasing concerns of the investors about reliability of accounting procedures and sales forecasts affected Salix intensely and the company revised its 2014 EPS forecasts from US$6.16 to US$5.20 and sales forecast from US$1.6bn to US$1.4bn. As a result, Salix shares plunged down almost 39% and Salix’s CFO, Adam Derbyshire, resigned. Even though Valeant has received many accusations on its strategy, as explained above, CEO Mr. Pearson contents the critiques pledged to disprove them by reporting earnings for Valeant’s existing business separately from the recent acquisitions for the rest of 2015. This means that the financials of Salix will be kept separate since Valeant wants to show its organic growth in the underlying business and once and for all prove that it is not just an acquisition machine. Financial Advisors Deutsche Bank and HSBC acted as financial advisors to Valeant while Centerview Partners and J.P. Morgan acted as financial advisors to Salix. Tags: Valeant, Salix, Pharma, Healtchare, M&A, Merge, Acquisition, Accounting, Accounting Scandal, Deutsche Bank, HSBC, Centerview Partners, J.P. Morgan, tax rate, synergies, R&D, CEO Pearson, Deal. All the views expressed are opinions of Bocconi Students Investment Club members and can in no way be associated with Bocconi University. All the financial recommendations offered are for educational purposes only. Bocconi Students Investment Club declines any responsibility for eventual losses you may incur implementing all or part of the ideas contained in this website. The Bocconi Students Investment Club is not authorised to give investment advice. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication by Bocconi Students Investment Club and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. Bocconi Students Investment Club does not receive compensation and has no business relationship with any mentioned company. Copyright © Feb-15 BSIC | Bocconi Students Investment Club .
Load more

Recommended publications
  • Faculty Disclosure
    Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role AbbVie, Allergan/ Tobira Therapeutics Inc, Gilead Research Grant Research Balart Sciences Inc, Pfizer, Salix Pharmaceuticals AbbVie, Merck Honorarium Advisory Board Bau None N/A N/A Benz None N/A N/A AbbVie, Arbutus Biopharma, Dieterich Gilead Sciences, Inc., Bristol- Research Grant Consultant Myers Squibb, Merck Bayer HealthCare Pharmaceuticals, Gilead Sciences Honorarium Speaking, Consultant Inc. Bristol-Myers Squibb, Gilead Speaking, Advisory Sciences, Inc, Salix Honorarium Frenette Board Pharmaceuticals, Inc, Merck Intercept Pharmaceuticals Honorarium Advisor Conatus Pharmaceuticals Inc Honorarium Consulting Principle Investigator, Research Grant, Han Gilead Sciences,
    [Show full text]
  • Manufacturers and Wholesalers Street
    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
    [Show full text]
  • Salix Pharmaceuticals, Inc. 2007 Annual Report and Form 10-K
    2007 Annual Report and Form 10-K Advancing Treatment in GastroenterologyTM Corporate Mission Statement Salix is committed to being the leading U.S. specialty pharmaceutical Company licensing, developing and marketing innovative products to health care professionals to prevent or treat gastrointestinal disorders in patients while providing rewarding opportunities for our employees and creating exceptional value for our stockholders. To Our Stockholders Despite the December 28, 2007 approval of three generic delivery of mesalamine, or 5-ASA, beginning in the small balsalazide products by the Office of Generic Drugs, Salix bowel and continuing throughout the colon. Wilmington succeeded in making substantial advances in its business Pharmaceuticals, which licensed metoclopramide-ZYDIS to during 2007. From a product development standpoint we us, is moving forward in seeking FDA approval to market made impressive strides toward accessing both the multi- this fast-dissolving formulation. At this time, Wilmington is billion dollar irritable bowel syndrome market as well as targeting a fourth quarter 2008 approval. We believe that the hepatic encephalopathy market. We also progressed in our specialized sales force is positioned to effectively our effort to expand our presence in the inflammatory commercialize this patient-friendly formulation of this bowel disease market. On the marketing and sales side, widely-prescribed agent, if and when approved. we grew OSMOPREP® and MOVIPREP® to command a 25% We expect the product development success share of the prescription bowel cleansing market and we achieved during 2007 to be followed by commercial continued to grow XIFAXAN. On the business development success during 2008, as we anticipate receiving responses front we broadened our portfolio with the acquisitions of from the Food and Drug Administration during 2008 PEPCID OS® and metoclopramide-ZYDIS®.
    [Show full text]
  • Spec Pharma M&A Transaction Multiples
    SECTOR REPORT FOURTH QUARTER 2016 Disclaimer All information set forth in this report (the “Overview”) has been synthesized by Bourne Capital Partners, L.L.C. (“BP”) or was obtained from publicly available sources. BP makes no express or implied representation or warranty as to the accuracy or completeness of the information contained herein. BP expressly disclaims any and all liability that may be based on all information set forth in the Overview, errors therein, or omissions therefrom. This Overview includes certain statements, estimates and projections provided by BP with respect to anticipated future performance. Such statements, estimates and projections reflect various assumptions made by BP concerning anticipated results, which reflect significant subjective judgments made by BP and as a result, may or may not prove to be correct. There can be no assurance that such projected results are attainable or will be realized. No express or implied representations or warranties are made as to the accuracy of such statements, estimates or projections. In furnishing the Overview, BP does not undertake any obligation to provide the recipient with access to any additional information, to correct any inaccuracies that may become apparent or to update or otherwise revise this Overview. This Overview is not an offer to sell or a solicitation of an offer to purchase securities or to engage in any other transaction. BP is a North Carolina (USA) limited liability company doing business as Bourne Partners with divisions in Healthcare Merchant Banking, Alternative Assets, Management Consulting and Investment Banking. Investment Banking services are offered by Bourne Partners Securities, LLC, a registered broker dealer, Member FINRA and SIPC.
    [Show full text]
  • Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis
    P0403 Long-term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study Vermeire S1, Panés J2, Chiorean M3, Peyrin-Biroulet L4, Zhang J5, Sands BE6, Lazin K5, Cabell CH5, Naik SU5, Klassen P5, Sandborn WJ7 1Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium; 2Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain; 3Division of Gastroenterology, Virginia Mason Medical Center, Seattle, WA, USA; 4Department of Gastroenterology, INSERM U954, Lorraine University, Vandoeuvre-lès-Nancy, France; 5Arena Pharmaceuticals, San Diego, CA, USA; 6Icahn School of Medicine at Mount Sinai, New York, NY, USA; 7University of California San Diego, La Jolla, CA, USA Introduction Results • Etrasimod is an oral, selective, sphingosine 1-phosphate receptors 1, Patient Disposition and Characteristics • Among patients achieving clinical response, clinical remission, or endoscopic Table 2. Summary of Adverse Events During the OLE in Patients Receiving Etrasimod 2 mg in the OLE (Safety Population) 4, and 5 (S1P1, S1P4, S1P5) modulator in development for treatment of • 118 patients (84% of DB completers) entered the OLE improvements at Week 12, treatment effects were maintained at EOT in 1 immune and inflammatory-mediated diseases — 112 patients (etrasimod safety population) received etrasimod 2 mg at the majority of patients (Figure 3) Etrasimod Etrasimod • The efficacy of etrasimod as induction therapy in adult patients with any point in the OLE Figure 3. Proportion of
    [Show full text]
  • Appendix 4: Detail Expenditures by Sponsor (Award Categories) Sponsor Name FY12 Exp
    Appendix 4: Detail Expenditures By Sponsor (Award Categories) Sponsor Name FY12 Exp. Federal NIH National Cancer Institute (NCI) $60,455,497 NIH National Heart, Lung, and Blood Institute (NHLBI) $52,360,642 NIH National Institute of Allergy and Infectious Diseases (NIAID) $49,477,570 NIH National Institute of Child Health and Human Development (NICHD) $37,797,457 Agency for International Development (USAID) $34,499,658 National Science Foundation (NSF) $30,033,145 NIH National Institute of General Medical Sciences (NIGMS) $29,655,157 NIH National Institute of Mental Health (NIMH) $25,435,686 NIH National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDKD) $23,042,270 Centers for Disease Control and Prevention (CDC) $16,568,876 US Department of Education (DOED) $15,111,132 NIH National Institute of Environmental Health Sciences (NIEHS) $15,077,598 NIH National Institute on Drug Abuse (NIDA) $14,494,964 NIH National Center for Research Resources (NCRR) $12,781,321 NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD) $10,297,162 NIH National Institute of Dental and Craniofacial Research (NIDCR) $9,769,057 NIH National Institute of Neurological Disorders and Stroke (NINDS) $9,498,790 NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA) $9,161,191 Department of Energy (DOE) $8,285,830 NIH National Human Genome Research Institute (NHGRI) $7,711,975 United States Environmental Protection Agency (EPA) $6,787,380 Agency for Healthcare Research and Quality (AHRQ) $6,520,417 Department of Homeland
    [Show full text]
  • Important Transaction and Tax Information Regarding the Exchange Transaction of Pharmaceutical Holdrs Trust Into Shares of Market Vectors Pharmaceutical Etf
    IMPORTANT TRANSACTION AND TAX INFORMATION REGARDING THE EXCHANGE TRANSACTION OF PHARMACEUTICAL HOLDRS TRUST INTO SHARES OF MARKET VECTORS PHARMACEUTICAL ETF For electing owners (“Exchange Participants”) of Pharmaceutical HOLDRS Trust (“PPH HOLDRS”), units of PPH HOLDRS were exchanged on December 20, 2011 for shares of Market Vectors Pharmaceutical ETF. For each PPH HOLDR receipt validly tendered, Exchange Participants received 1 share of Market Vectors Pharmaceutical ETF. This exchange was effected through a series of transfers and rebalance transactions (sales transactions in certain securities underlying the PPH HOLDRS and purchase transactions in new securities for exchange into Market Vectors Pharmaceutical ETF). These transactions were authorized by the Exchange Participant and executed on their behalf. As a result of the rebalance transactions, part of this exchange may result in a taxable event and cost basis adjustments to the Exchange Participant. Provided is a breakdown of the exchange transactions and tax implications based on a ‘PPH HOLDR trading unit” (100 PPH HOLDRS receipts) 1. For each PPH HOLDR Trading Unit tendered, BNY Mellon Shareowner Services as Exchange Agent for the exchange offer, delivered the following securities per PPH HOLDR Trading Unit to BNY ConvergEx Execution Solutions LLC (“ConvergEx”), acting in its capacity transition manager in connection with the exchange offer. The total value of these securities transferred per PPH HOLDR Trading Unit, based on the December 20, 2011 market close, was $7,191.63.
    [Show full text]
  • FY06 Pharmaceutical Marketing Disclosures Report
    Pharmaceutical Marketing Disclosures For the period July 1, 2005 to June 30, 2006 Report of Vermont Attorney General William H. Sorrell June 26, 2007 Contact: Julie Brill Assistant Attorney General (802) 828-5479 Pharmaceutical Marketing Disclosures: Report of Vermont Attorney General William H. Sorrell on Payments to Physicians June 26, 2007 Index Page: I. Executive Summary 3 II. Description of Vermont’s Payment Disclosure Law 4 III. Amendments to Prior Pharmaceutical Marketing Disclosure Reports filed by the Vermont Attorney General's Office 5 IV. Summary of Pharmaceutical Marketing Expenditures 6 1. Total Payments of Each Pharmaceutical Manufacturer 6 2. Payments of all Manufacturers Organized by Recipient Type 7 3. Payments by Nature of Expenditure 10 4. Payments by Purpose of Expenditure 10 5. Trade Secret Declarations 11 V. Enforcement Actions 12 Appendix: Tab 1: 33 V.S.A. §2005 13 Tab 2: FY 06 Tables 17 Tab 3: FY 05 Tables as Revised 25 Tab 4: FY 04 Tables as Revised 34 Tab 5: FY 03 Tables as Revised 43 2 Pharmaceutical Marketing Disclosures: Report of Vermont Attorney General William H. Sorrell on Payments to Physicians June 26, 2007 I. Executive Summary This is the fourth report of Vermont Attorney General William H. Sorrell on Pharmaceutical Marketing Disclosures. It is based upon disclosures pertaining to payments made during the period July 1, 2005, through June 30, 2006 (FY 06) by pharmaceutical marketers, of the amount of money the companies paid during the past fiscal year on consulting and speaker fees, travel expenses, gifts, and other payments to physicians, hospitals, universities and others authorized to prescribe or dispense pharmaceutical products.
    [Show full text]
  • Appendix 1: Detail Awards by Sponsor
    Appendix 1: Detail Awards By Sponsor Sponsor Name FY12 Award Federal National Cancer Institute $50,418,830 National Institute of Allergy and Infectious Diseases $46,180,948 US Agency for International Development $37,208,131 National Science Foundation - Research (NSF) $32,365,368 National Institute of Child Health and Human Development (NICHD) $31,370,905 National Heart Lung and Blood Institute (NHLBI) $30,091,872 National Institute of Diabetes, Digestive and Kidney Diseases $24,989,100 National Institute of General Medicine Science $22,515,093 National Institute of Mental Health-NIH $19,346,563 National Heart Lung and Blood Institute $15,390,835 US Department of Education $15,016,549 National Institute on Drug Abuse $12,872,528 NIH National Center for Advancing Translational Sciences (NCATS) $12,546,906 National Institute of Environmental Health Sciences $12,130,116 National Institute on Alcohol Abuse and Alcoholism $11,320,987 National Institute of Arthritis Musculoskeletal Skin Disease $10,112,508 Centers for Disease Control $9,028,629 National Institute of Dental and Craniofacial Research $8,401,136 National Institute of Neurologic Disorders and Stroke $8,378,473 Bureau of Health Professions $8,085,816 US Department of Homeland Security $5,699,790 US Department of Energy $5,266,325 Centers for Disease Control and Prevention (CDC) $4,615,173 Agency for Healthcare Research and Quality $4,547,997 US Army Medical Research $4,534,927 NIH National Heart, Lung, and Blood Institute (NHLBI) $4,425,558 US Environmental Protection Agency -
    [Show full text]
  • Marketer1 Year of Initial Investment Investment
    YEAR OF INITIAL INVESTMENT COUNTERPARTY PRODUCT(S) MARKETER1 INVESTMENT VEHICLE Artes Medical, Inc. Bellafill, Puregraft, HD PRP Artes Medical, Inc. 2008 HCR 1 Vertex Pharmaceuticals, Inc. Lexiva ViiV Healthcare UK Limited 2008 HCR 1 Dyax Corp. Phage display platform Multiple 2008 HCR 1, SMA Undisclosed Sanctura, Sanctura XR Allergan, Inc. 2008 HCR 1 Shore Therapuetics, Inc. Fenoglide Sciele Pharma, Inc. 2008 HCR 1 Undisclosed Oracea, Sanctura XR Galderma S.A. / Allergan, Inc. 2008 HCR 1, HCR 2 AEterna Zentaris, Inc. Cetrotide Merck Serono S.A. 2008 HCR 1 NeurogesX, Inc. Qutenza Astellas Pharma Inc. 2010 HCR 1 Undisclosed Undisclosed vaccine Undisclosed 2010 HCR 1 Undisclosed Myozyme Genzyme Corp. / Sanofi-Aventis U.S. LLC 2011 HCR 1 Inventor (undisclosed) Krystexxa Savient Pharmaceuticals, Inc. 2011 HCR 1 Undisclosed Undisclosed vaccine Undisclosed 2010 HCR 2 Zogenix, Inc. Sumavel Dosepro, Zohydro Zogenix, Inc. 2011 HCR 2 AcuFocus, Inc. Kamra Inlay, IOL AcuFocus, Inc. 2011 HCR 2 Inventor Cervarix GlaxoSmithKline plc 2011 HCR 2 Stereotaxis, Inc. RMT Ablation Catheters Biosense Webster, Inc. 2011 HCR 2 Helomics Corporation ChemoFx, GeneFx Lung, GeneFx Colon, BioSpeciFx Helomics Corporation 2012 HCR 2 Raptor Pharmacuetical Corp. Procysbi Raptor Pharmacuetical Corp. 2012 HCR 2, SMA Undisclosed Undisclosed Undisclosed 2012 HCR 2 Nuron Biotech, Inc. Meningitec, HibTITER Nuron Biotech, Inc. 2012 HCR 2 Medigene AG Eligard Astellas Pharma Inc. 2012 HCR 2 Undisclosed Lyrica Pfizer, Inc. 2012 HCR 2, SMA Ironwood Pharmaceuticals, Inc. Linzess Allergan, Inc. 2012 SMA TearScience, Inc. LipiView, LipiFlow TearScience, Inc. 2013 HCR 2 Undisclosed Inavir Daiichi Sankyo Company, Limited 2013 HCR 2 Undisclosed Benlysta GlaxoSmithKline plc 2013 HCR 2 Suneva Medical, Inc.
    [Show full text]
  • Manufacturers and Wholesalers Street City ST Zip Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Road, Dept
    2018 AB128 Code of Conduct Compliant Companies report Manufacturers and Wholesalers Street City ST Zip Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accutron Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acell, Inc. 6640 Eli Whitney Drive, Suite 200 Columbia MD 21046 Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne PA 19087 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Adamas Pharmaceuticals, Inc. 1900 Powell St., Suite 750 Emeryville CA 94608 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products Services, Inc. Aegerion Pharmaceuticals, Inc. One Main Street, Suite 800 Cambridge MA 02142 Aerie Pharmaceuticals, Inc. 2030 Main St., Suite 1400 Irvine CA 92614 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS Inc. Akrimax Pharmaceuticals, LLC 11 Commerce Drive, 1st Floor Cranford NJ 07016 Alamo Pharma Services, Inc. Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alden Optical Laboratories, Inc. Aldenex Vision LLC Alimera Sciences, Inc. 6120 Windward Parkway, Suite 290 Alpharetta GA 30005 Alkermes, Inc.
    [Show full text]
  • Speciality Players Define M&A As Big Pharma Seeks Focus
    May 26, 2015 Speciality players define M&A as big pharma seeks focus Jonathan Gardner Forget megamergers. For half a decade the daring deals in the pharma space have been made primarily by the speciality players. Endo International’s move on Par Pharmaceutical last week shows how this peer group has defined M&A since 2009, when Pfizer and Merck & Co made the last major acquisitions of companies regarded as traditional big pharmas, those of Wyeth and Schering-Plough respectively. One company alone, Actavis, has been responsible for nearly a third of the value of the top 25 deals in this time, transforming itself from a respectably sized generics company into the world’s second-biggest seller of skin and eye disease drugs (see table below). Tax pressure To be sure, big pharma companies have been active acquirers, but their activities have been confined primarily to achievable bolt-on transactions to bring in interesting developmental assets or promising business lines, not the megamergers that tend to grab headlines. Two deals proposed and then abandoned last year might have changed this picture substantially and moved nearly $150bn onto the side of big pharma. AstraZeneca successfully fought off Pfizer, however, and AbbVie had a near-miss with its takeout of Shire – scuttled because of changes to US tax rules. In fact it was speciality companies rather than pharma giants that wrung most of the value from tax deals before laws making inversions much less appealing were enacted. Before Actavis became the world’s 19th biggest seller of prescription drugs, and on its way to a top 10 ranking, it was known as Watson Pharmaceuticals.
    [Show full text]